PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
M Amine Bouhlel, Bruno Derudas, Elena Rigamonti, Rébecca Dièvart, John Brozek, Stéphan Haulon, Christophe Zawadzki, Brigitte Jude, Gérard Torpier, Nikolaus Marx, Bart Staels, Giulia Chinetti-Gbaguidi, M Amine Bouhlel, Bruno Derudas, Elena Rigamonti, Rébecca Dièvart, John Brozek, Stéphan Haulon, Christophe Zawadzki, Brigitte Jude, Gérard Torpier, Nikolaus Marx, Bart Staels, Giulia Chinetti-Gbaguidi
Abstract
Th1 cytokines promote monocyte differentiation into proatherogenic M1 macrophages, while Th2 cytokines lead to an "alternative" anti-inflammatory M2 macrophage phenotype. Here we show that in human atherosclerotic lesions, the expression of M2 markers and PPARgamma, a nuclear receptor controlling macrophage inflammation, correlate positively. Moreover, PPARgamma activation primes primary human monocytes into M2 differentiation, resulting in a more pronounced anti-inflammatory activity in M1 macrophages. However, PPARgamma activation does not influence M2 marker expression in resting or M1 macrophages, nor does PPARgamma agonist treatment influence the expression of M2 markers in atherosclerotic lesions, indicating that only native monocytes can be primed by PPARgamma activation to an enhanced M2 phenotype. Furthermore, PPARgamma activation significantly increases expression of the M2 marker MR in circulating peripheral blood mononuclear cells. These data demonstrate that PPARgamma activation skews human monocytes toward an anti-inflammatory M2 phenotype.
Source: PubMed